The aim of this systematic review and meta-analysis is to evaluate the effectiveness of SGLT-2 inhibitors in improving hepatic steatosis and hepatic fibrosis in patients with NAFLD. Here, SLC5A2 is linked to metabolic dysfunction-associated steatotic liver disease.